Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial

B-305 Study Investigators

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Rationale: Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. Objectives: To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic fibrosis (CF) bronchiectasis. Secondary endpoints included time to first exacerbation, duration of exacerbations, antibiotic use for exacerbations and quality of life (QOL) (St George's Respiratory Questionnaire, SGRQ). Methods: Patients with non-CF bronchiectasis and a history of chronic excess production of sputum and ≥2 pulmonary exacerbations in the previous 12 months were randomised (1:1) to 52 weeks treatment with inhaled mannitol 400 mg or low-dose mannitol control twice a day. Patients were 18-85 years of age, baseline FEV1 ≥40% and ≤85% predicted and a baseline SGRQ score ≥30. Main results: 461 patients (233 in the mannitol and 228 in the control arm) were treated. Baseline demographics were similar in the two arms. The exacerbation rate was not significantly reduced on mannitol (rate ratio 0.92, p=0.31). However, time to first exacerbation was increased on mannitol (HR 0.78, p=0.022). SGRQ score was improved on mannitol compared with low-dose mannitol control (-2.4 units, p=0.046). Adverse events were similar between groups. Conclusions: Mannitol 400 mg inhaled twice daily for 12 months in patients with clinically significant bronchiectasis did not significantly reduce exacerbation rates. There were statistically significant improvements in time to first exacerbation and QOL. Mannitol therapy was safe and well tolerated. Trial registration number: NCT00669331.

Original languageEnglish (US)
Pages (from-to)1073-1079
Number of pages7
JournalThorax
Volume69
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Bronchiectasis
Mannitol
Fibrosis
Randomized Controlled Trials
Quality of Life
Mucociliary Clearance
Lung
Mucus
Sputum
Demography
Clinical Trials
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Inhaled mannitol for non-cystic fibrosis bronchiectasis : A randomised, controlled trial. / B-305 Study Investigators.

In: Thorax, Vol. 69, No. 12, 01.12.2014, p. 1073-1079.

Research output: Contribution to journalArticle

B-305 Study Investigators. / Inhaled mannitol for non-cystic fibrosis bronchiectasis : A randomised, controlled trial. In: Thorax. 2014 ; Vol. 69, No. 12. pp. 1073-1079.
@article{30f4bccdcd804a828f24a9a23c4077fa,
title = "Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial",
abstract = "Rationale: Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. Objectives: To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic fibrosis (CF) bronchiectasis. Secondary endpoints included time to first exacerbation, duration of exacerbations, antibiotic use for exacerbations and quality of life (QOL) (St George's Respiratory Questionnaire, SGRQ). Methods: Patients with non-CF bronchiectasis and a history of chronic excess production of sputum and ≥2 pulmonary exacerbations in the previous 12 months were randomised (1:1) to 52 weeks treatment with inhaled mannitol 400 mg or low-dose mannitol control twice a day. Patients were 18-85 years of age, baseline FEV1 ≥40{\%} and ≤85{\%} predicted and a baseline SGRQ score ≥30. Main results: 461 patients (233 in the mannitol and 228 in the control arm) were treated. Baseline demographics were similar in the two arms. The exacerbation rate was not significantly reduced on mannitol (rate ratio 0.92, p=0.31). However, time to first exacerbation was increased on mannitol (HR 0.78, p=0.022). SGRQ score was improved on mannitol compared with low-dose mannitol control (-2.4 units, p=0.046). Adverse events were similar between groups. Conclusions: Mannitol 400 mg inhaled twice daily for 12 months in patients with clinically significant bronchiectasis did not significantly reduce exacerbation rates. There were statistically significant improvements in time to first exacerbation and QOL. Mannitol therapy was safe and well tolerated. Trial registration number: NCT00669331.",
author = "{B-305 Study Investigators} and Diana Bilton and Gregory Tino and Alan Barker and Chambers, {Daniel C.} and {De Soyza}, Anthony and Dupont, {Lieven J A} and Conor O'Dochartaigh and {Van Haren}, {Eric H J} and Vidal, {Luis Otero} and Tobias Welte and Fox, {Howard G.} and Jian Wu and Brett Charlton",
year = "2014",
month = "12",
day = "1",
doi = "10.1136/thoraxjnl-2014-205587",
language = "English (US)",
volume = "69",
pages = "1073--1079",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Inhaled mannitol for non-cystic fibrosis bronchiectasis

T2 - A randomised, controlled trial

AU - B-305 Study Investigators

AU - Bilton, Diana

AU - Tino, Gregory

AU - Barker, Alan

AU - Chambers, Daniel C.

AU - De Soyza, Anthony

AU - Dupont, Lieven J A

AU - O'Dochartaigh, Conor

AU - Van Haren, Eric H J

AU - Vidal, Luis Otero

AU - Welte, Tobias

AU - Fox, Howard G.

AU - Wu, Jian

AU - Charlton, Brett

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Rationale: Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. Objectives: To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic fibrosis (CF) bronchiectasis. Secondary endpoints included time to first exacerbation, duration of exacerbations, antibiotic use for exacerbations and quality of life (QOL) (St George's Respiratory Questionnaire, SGRQ). Methods: Patients with non-CF bronchiectasis and a history of chronic excess production of sputum and ≥2 pulmonary exacerbations in the previous 12 months were randomised (1:1) to 52 weeks treatment with inhaled mannitol 400 mg or low-dose mannitol control twice a day. Patients were 18-85 years of age, baseline FEV1 ≥40% and ≤85% predicted and a baseline SGRQ score ≥30. Main results: 461 patients (233 in the mannitol and 228 in the control arm) were treated. Baseline demographics were similar in the two arms. The exacerbation rate was not significantly reduced on mannitol (rate ratio 0.92, p=0.31). However, time to first exacerbation was increased on mannitol (HR 0.78, p=0.022). SGRQ score was improved on mannitol compared with low-dose mannitol control (-2.4 units, p=0.046). Adverse events were similar between groups. Conclusions: Mannitol 400 mg inhaled twice daily for 12 months in patients with clinically significant bronchiectasis did not significantly reduce exacerbation rates. There were statistically significant improvements in time to first exacerbation and QOL. Mannitol therapy was safe and well tolerated. Trial registration number: NCT00669331.

AB - Rationale: Bronchiectasis is characterised by excessive production of mucus and pulmonary exacerbations. Inhaled osmotic agents may enhance mucociliary clearance, but few long-term clinical trials have been conducted. Objectives: To determine the impact of inhaled mannitol on exacerbation rates in patients with non-cystic fibrosis (CF) bronchiectasis. Secondary endpoints included time to first exacerbation, duration of exacerbations, antibiotic use for exacerbations and quality of life (QOL) (St George's Respiratory Questionnaire, SGRQ). Methods: Patients with non-CF bronchiectasis and a history of chronic excess production of sputum and ≥2 pulmonary exacerbations in the previous 12 months were randomised (1:1) to 52 weeks treatment with inhaled mannitol 400 mg or low-dose mannitol control twice a day. Patients were 18-85 years of age, baseline FEV1 ≥40% and ≤85% predicted and a baseline SGRQ score ≥30. Main results: 461 patients (233 in the mannitol and 228 in the control arm) were treated. Baseline demographics were similar in the two arms. The exacerbation rate was not significantly reduced on mannitol (rate ratio 0.92, p=0.31). However, time to first exacerbation was increased on mannitol (HR 0.78, p=0.022). SGRQ score was improved on mannitol compared with low-dose mannitol control (-2.4 units, p=0.046). Adverse events were similar between groups. Conclusions: Mannitol 400 mg inhaled twice daily for 12 months in patients with clinically significant bronchiectasis did not significantly reduce exacerbation rates. There were statistically significant improvements in time to first exacerbation and QOL. Mannitol therapy was safe and well tolerated. Trial registration number: NCT00669331.

UR - http://www.scopus.com/inward/record.url?scp=84919692674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919692674&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2014-205587

DO - 10.1136/thoraxjnl-2014-205587

M3 - Article

C2 - 25246664

AN - SCOPUS:84919692674

VL - 69

SP - 1073

EP - 1079

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 12

ER -